Taking stock of the drug industry, from the lab to the medicine chestFebruary 21, 2023Check out STAT+Sponsored ByBy Ed SilvermanPharmalot Columnist, Senior Writer Kim Raff for STAT 'Caught in the middle': A battle between Vertex and insurers is leaving cystic fibrosis patients with crushing drug costs A growing number of cystic fibrosis patients are struggling with drug costs due to a battle between drugmakers and insurers. By Ed Silverman STAT+ | Dutch group sues AbbVie for human rights violations stemming from Humira pricing "Access to care and right to life are fundamental rights (or human rights) that AbbVie must respect," the Dutch public interest group argued. By Ed Silverman Opinion: Tobacco companies pledge 'harm reduction' but are doing the opposite Big Tobacco's "harm reduction" seems to be marketing nicotine-laden vaping products and lobbying against regulating traditional cigarettes. By Howard K. Koh and Michael Fiore Alissa Ambrose/STAT Cereal, pasta, and other food companies blast the FDA for a too-strict definition of 'healthy' The companies behind America's favorite culinary indulgences are upset their foods wouldn't be "healthy" under a recent FDA proposal. By Nicholas Florko STAT+ | Antibody treatment benefits leukemia patients receiving bone marrow transplant The antibody-radiation treatment, called Iomab-B, is being developed by Actinium Pharmaceuticals, a small drugmaker based in New York. By Adam Feuerstein More around STATCheck out more exclusive coverage with a STAT+ subscriptionRead premium in-depth biotech, pharma, policy, and life science coverage and analysis with all of our STAT+ articles.Enjoying Pharmalot? Tell us about your experienceContinue reading the latest health & science news with the STAT appDownload on the App Store or get it on Google Play STAT, 1 Exchange Place, Boston, MA©2023, All Rights Reserved.I no longer wish to receive STAT emailsUpdate Newsletter Preferences • Contact Us • Advertise with Us • View in Browser
No comments